Infectious Disease

Top news of the day from across the health care landscape.

Researchers seek to induce broadly neutralizing antibodies to block numerous HIV variants.

New class of HIV medications called viral-entry inhibitors protect healthy cells from viral infection.

HIV infection rate among gay and bisexual men remains a problem.

Growing HIV incidence in young individuals could cause epidemic to become worse.

Study sheds light on HIV development.

Care coordination with case management now found to improve HIV viral suppression in hospitalized patients.

Maternal antiretroviral therapy decreases the threat of HIV transmission through breast milk.

Interaction between HIV and the immune system are crucial to eradicating the disease.

CDC finds need for interventions to improve HIV testing rates among men between 15- and 39-years-old.

New analysis may lead to the development of new antiviral HIV drugs.

Antiretroviral therapy may alleviate some cognitive problems among HIV-positive patients.

List prices for Complera and Stribild continue to rise for HIV treatment.

Off-label rilpivirine in combination with emtricitabine and tenofovir may help reduce out-of-pocket spending for patients with HIV.

The CDC recently issued an alert warning health care facilities about Candida auris, an emerging multidrug-resistant yeast.

Infants can quickly produce novel antibodies that protect against HIV.

Antiretroviral therapy use and viral suppression heavily impacted by issues such as poverty and race.

Some injection drug users with HIV and hepatitis C seem to have the same immune problems as the elderly.

Protease inhibitors can frequently lead to cardiovascular disease, diabetes, and obesity.

Engineering bacteria to deliver HIV-1 neutralizing antibodies at the site where the virus enters the body may offer a cost-effective barrier to HIV-1 transmission.

HIV-like virus eliminated from body with early administration of treatment.

Further research is needed for HIV to be treated by the CRISPR/Cas9 gene editing tool.

Protease inhibitors can lead to the development of cardiovascular disease, diabetes, and obesity in patients with HIV.

Harnessing the immune system may lead to an effective HIV vaccine strategy.

Greater education programming needed for patients at-risk for HIV infection.